Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From BioXell S.p.A.
New chief financial officer Thad Huston said that Galapagos was evaluating “various strategic options for Jyseleca,” the company’s only revenue source, given that the landscape for the JAK class in Europe “has changed significantly over the past six months.”
Kite’s senior director and head of medical affairs, Intercontinental Region, Tony Li, talks to Scrip about the company's efforts to enable timely and broad access to Yescarta in Singapore, where wider cancer drug procurement prices have declined following policy changes. A patient is already on course to being prepped for Kite's CAR-T cell therapy.
Plus deals involving Sanofi/Adocia, Sirnaomics/EDIRNA, Eisai/DRI Healthcare, Sangamo/Voyager, Liquidia/Pharmosa, Tonix/Upsher-Smith and more.
A Friends of Cancer Research working group suggests that the US FDA can learn lessons from the approval of Gilead/Kite’s second CAR-T therapy Tecartus that can help expedited iterative development of cell therapies more broadly.
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.